Distribuzione geografica
Continente #
NA - Nord America 24.247
EU - Europa 2.499
AS - Asia 596
AF - Africa 22
SA - Sud America 19
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 1
Totale 27.396
Nazione #
US - Stati Uniti d'America 24.214
DE - Germania 396
IT - Italia 387
IE - Irlanda 359
SE - Svezia 339
UA - Ucraina 296
CN - Cina 273
KR - Corea 233
PL - Polonia 213
FR - Francia 174
GB - Regno Unito 137
FI - Finlandia 87
RU - Federazione Russa 39
CA - Canada 31
BE - Belgio 21
HK - Hong Kong 21
NL - Olanda 21
VN - Vietnam 21
CM - Camerun 13
SG - Singapore 11
EU - Europa 10
JP - Giappone 10
BR - Brasile 8
RO - Romania 8
ES - Italia 7
CL - Cile 6
CH - Svizzera 5
CZ - Repubblica Ceca 5
IN - India 5
ZA - Sudafrica 4
IR - Iran 3
TR - Turchia 3
BD - Bangladesh 2
EC - Ecuador 2
EG - Egitto 2
IL - Israele 2
KG - Kirghizistan 2
SA - Arabia Saudita 2
UG - Uganda 2
UZ - Uzbekistan 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
AT - Austria 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IQ - Iraq 1
KE - Kenya 1
LB - Libano 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 27.396
Città #
Woodbridge 6.938
Wilmington 6.854
Houston 5.412
Fairfield 899
Chandler 564
Ann Arbor 514
Ashburn 405
Seattle 377
Dublin 322
Cambridge 307
Jacksonville 253
Medford 234
Kraków 213
Rome 189
Dearborn 176
Beijing 135
New York 134
Lawrence 110
San Diego 58
Zhengzhou 51
Menlo Park 49
Mülheim 41
Milan 34
Creede 30
London 30
Falls Church 25
Dong Ket 20
Boardman 19
Brussels 19
Hong Kong 19
Phoenix 19
Colorado Springs 17
Helsinki 16
Redwood City 14
Nanjing 13
Norwalk 13
Palo Alto 13
Seoul 13
University Park 12
Florence 11
San Francisco 11
Toronto 11
Cedarhurst 10
Kunming 10
Mountain View 10
Santa Clara 10
Lappeenranta 9
Verona 9
Nuremberg 8
Amsterdam 6
Dundas 6
Guangzhou 6
Hefei 6
Manitou Springs 6
Ottawa 6
Saint Petersburg 6
San Jose 6
Hounslow 5
Jinan 5
Los Angeles 5
Nürnberg 5
Olomouc 5
Acton 4
Berlin 4
Hangzhou 4
Kilburn 4
New Bedfont 4
North Bergen 4
Palermo 4
San Mateo 4
Shanghai 4
São Paulo 4
Tokyo 4
Atlanta 3
Buzau 3
Chengdu 3
Civitavecchia 3
Detroit 3
Indiana 3
Montréal 3
Nanchang 3
Prescot 3
Redmond 3
Rotterdam 3
Shenyang 3
Siena 3
The Dalles 3
Auburn Hills 2
Avellino 2
Binasco 2
Bologna 2
Cagliari 2
Casavatore 2
Castiglione delle Stiviere 2
Central District 2
Chiswick 2
Chongqing 2
Engelhard 2
Faimes 2
Fuzhou 2
Totale 24.845
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 489
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 479
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 441
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 432
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 424
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 420
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 420
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 420
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 416
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 415
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 413
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 413
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 411
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 411
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 400
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 399
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 397
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 390
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 385
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 385
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 383
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 379
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 377
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 373
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 373
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 372
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 371
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 367
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 366
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 366
Dynamics of NRTI resistance mutations during therapy interruption 364
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 362
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 362
Temporal change in the use of genotypic resistance testing over the years 1999--2003 360
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 359
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 355
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 353
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 351
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 346
Clinical relevance of genotypic resistance testing today 346
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 344
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 344
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 343
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 343
HIV-1 non-B subtypes in Italy: a growing trend 336
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 334
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 334
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 333
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 333
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 331
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 327
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 327
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 327
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 326
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 322
HIV-1 Genetic Variability and Clinical Implications 320
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 318
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 317
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 315
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 300
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 291
Impact of pre-therapy viral load on virological response to modern first-line HAART 290
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 287
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 285
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 280
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 268
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 254
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 251
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 235
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 189
Is the rate of virological failure to cART continuing to decline in recent calendar years? 170
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 169
HIV MDR is still a relevant issue despite its dramatic drop over the years 166
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 163
Genetic diversity of HIV type 1 in Montenegro 156
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 154
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 153
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 140
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 132
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 128
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 99
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 95
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 89
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 69
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 55
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 49
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 44
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 44
Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon 42
Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database 40
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 39
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 37
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 37
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 35
Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV 31
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 31
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen 29
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry 28
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 27
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 26
Totale 27.326
Categoria #
all - tutte 61.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.297

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019603 0 0 0 0 0 0 0 0 0 0 0 603
2019/20207.435 586 549 497 647 632 853 728 646 654 661 459 523
2020/20214.601 489 544 524 624 419 515 613 413 85 122 153 100
2021/20221.388 57 81 83 53 62 91 56 42 359 132 57 315
2022/20231.717 174 141 88 183 161 355 116 169 139 38 105 48
2023/2024592 80 18 32 25 55 132 37 18 19 138 11 27
Totale 27.969